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INTRODUCTION 
 
Dendritic cells (DCs) are specialized sentinels of the 
immune system responsible for coordinating adaptive 
immune responses [1]. In addition, during the steady-
state, DCs are also responsible for preventing aberrant 
immune activation, which is achieved through a tight 
regulation of DC environmental sensitivity, maturation, 
and life span. DCs arise from a hematopoietic lineage 
distinct from other leukocytes [2]. Two main DC 
subpopulations have been identified in so far: myeloid 
conventional DCs (cDCs), and plasmacytoid DCs 
(pDCs). cDCs exist in the peripheral tissues,  in  second- 
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ary lymphoid organs, and in the peripheral blood [1, 2]. 
cDCs have a dendritic shape and exhibit typical DC 
functions, such as antigen uptake, processing, and 
presentation. cDCs are largely deputed to IL-12 
production and to the general orchestration of antigen-
specific immune responses [2]. pDCs can be both of 
myeloid and lymphoid origin and they are primarily in 
charge for secreting type I interferons in response to 
viruses [1, 2]. 
 
Impaired DC function is a hallmark of many types of 
disorders, including cancer [3], and is commonly 
observed during aging, too, contributing to reduce 
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Abstract: Dendritic cells (DCs) are antigen‐presenting cells that critically influence decisions about immune activation or
tolerance. Impaired DC function is at the core of common chronic disorders and contributes to reduce immunocompetence
during  aging.  Knowledge  on  the  mechanisms  regulating  DC  generation  and  function  is  necessary  to  understand  the
immune system and to prevent disease and immunosenescence. Here we show that the sirtuin Sirt6, which was previously
linked  to  healthspan  promotion,  stimulates  the  development  of  myeloid,  conventional  DCs  (cDCs).  Sirt6‐knockout
(Sirt6KO) mice  exhibit  low  frequencies  of  bone marrow  cDC  precursors  and  low  yields  of  bone marrow‐derived  cDCs
compared to wild‐type (WT) animals. Sirt6KO cDCs express lower levels of class II MHC, of costimulatory molecules, and of
the  chemokine  receptor  CCR7,  and  are  less  immunostimulatory  compared  to  WT  cDCs.  Similar  effects  in  terms  of
differentiation  and  immunostimulatory  capacity were  observed  in  human monocyte‐derived DCs  in  response  to  SIRT6
inhibition. Finally, while Sirt6KO cDCs show an overall reduction in their ability to produce IL‐12, TNF‐α and IL‐6 secretion
varies dependent on the stimulus, being reduced in response to CpG, but increased in response to other Toll‐like receptor
ligands.  In  conclusion,  Sirt6  plays  a  crucial  role  in  cDC  differentiation  and  function  and  reduced  Sirt6  activity  may
contribute to immunosenescence. 
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immune competence, but also predisposing to 
inflammation through aberrant cytokine production (i.e. 
IL-6 and TNF-α) [4-6]. Defining the mechanisms that 
underlie DC lineage commitment, differentiation, 
maturation and function represents a key challenge 
which will improve our understanding of the balance 
between immunity and tolerance and possibly also lead 
to new strategies to boost immune competence and 
avoid unwanted inflammation. 
 
The NAD+-dependent deacetylase Sirt6, a protein 
involved in genome maintenance and in metabolic 
homeostasis, exerts protective functions against age-
related diseases and was shown to extend life span in 
mice [7-9]. In turn, a decline in Sirt6 expression [10, 11] 
and/or in its function (as a result of reduced availability 
of tissue NAD+) [12] are postulated to contribute to 
human aging [8]. Quite remarkably, some of Sirt6’s 
protective roles appear to reflect a role in immune 
regulation for it. Specifically, Sirt6 contributes to the 
release of TNF-α, a cytokine that is critically required for 
immune competence, via direct deacylation of TNF-α 
itself [2, 13-15]. Data from our laboratory indicate that 
Sirt6 also favours the secretion of IFN-γ and of the pro-
chemotactic cytokine CXCL8 via O-acetyl-ADP-ribose 
production and consequent activation of the TRPM2 
cation channel, and of Ca2+ signalling downstream of it 
[13, 16, 17]. In addition, a role for Sirt6 in the resolution 
of inflammation has also been proposed based on the 
detection of inflammatory infiltrates in tissues from Sirt6 
knockout (Sirt6KO) mice [9, 18] and on the ability of 
Sirt6 to reduce NF-κB and c-JUN activity [18, 19] as 
well as glycolysis in activated T cells [20]. 
 
Sirt6 is expressed in bone marrow (BM)-derived cDCs 
(BMDCs) [15]. Nevertheless, the contribution of this 
enzyme to the biology of this important leukocyte 
subset remains presently unknown. Taking advantage of 
the availability of Sirt6KO mice [9], we focused on the 
role of Sirt6 in the differentiation, maturation and 
function of BMDCs generated with granulocyte-
macrophage colony-stimulating factor (GM-CSF) [21, 
22], and, making use of a chemical SIRT6 inhibitor 
[23], we validated our findings in human monocyte-
derived DCs (moDCs). We identify a novel, key role for 
Sirt6 in cDC biology. 
 
RESULTS 
 
Sirt6 promotes cDC lineage commitment 
 
Culturing mouse BM in the presence of GM-CSF 
typically results in the generation of large amounts of 
CD11c+ BMDCs that, by day 8 of culture, reach a 70% 
purity and typically comprise a mixture of immature 
and mature BMDCs [21, 22]. Thus, this model was first 
used to compare BMDCs from wild type (WT) and 
Sirt6KO mice and thereby assess a potential role for 
Sirt6 in cDC development. The yield of CD11c+ 
BMDCs from BMs harvested from Sirt6KO mice was 
typically lower than that obtained with WT BMs 
(Figure 1A). Time course experiments demonstrated 
how already at early time points the rates of CD11c+ 
BM cells cultured with GM-CSF were lower when Sirt6 
was missing (Figure 1B), suggesting that the observed 
difference may reflect, at least in part, a reduced 
representation of the myeloid cDCs lineage in the BM 
of Sirt6KO mice. Consistent with this hypothesis, an ex 
vivo analysis showed a significant reduction in 
CD11c+/MHCII- cells (cDC precursors, pre-cDCs) in 
the BM of Sirt6KO mice as compared to the control 
mice (Figure 1C, D). Quite remarkably, Sirt6 deficiency 
had no effect on the representation of pDCs in the BM 
(Figure 1D), while other mature myeloid subsets, such 
as granulocytes and mono/macrophages were even more 
represented in Sirt6KO BM than in WT BM. Studies of 
early myeloid precursors demonstrated a reduced 
frequency of common myeloid progenitors (CMP) and 
of megakaryocyte-erythroid progenitors (MEP) in 
Sirt6KO BM in favor of an expansion of granulocyte 
macrophage progenitors (GMP) (Figure 1E), the latter 
finding being consistent with the detection of increased 
frequencies of granulocytes and macrophages in 
Sirt6KO BM (Figure 1D). Notably, peripheral blood 
hematology performed in animals aged 17-18 days 
revealed no effect of Sirt6 deletion on total white blood 
cell counts (which, however, did not discriminate 
between the different white blood cell subsets), while a 
reduced mean corpuscular hemoglobin concentration as 
well as reduced platelets counts in Sirt6KO mice could 
be documented (Supplementary Table 1). Overall, the 
previous experiments demonstrated that Sirt6 deletion 
reduces cDC lineage commitment and that a reduced 
frequency of CMP and of cDC precursors is likely to 
contribute to the reduced yield of CD11c+ BMDCs 
observed in vitro with Sirt6KO BM. 
 
TNF-α is a pleiotropic cytokine whose role in regulating 
hematopoiesis and cDC generation has been 
documented in both human and mice [24, 25]. In turn, 
Sirt6 was previously reported to promote TNF-α 
secretion [13, 15, 16]. Indeed, consistent with these 
studies, reduced TNF-α concentrations were detected in 
BMDC supernatants from Sirt6KO mice compared to 
WT BMDCs (Figure 1F). Thus, we hypothesized that a 
reduced TNF-α availability in Sirt6KO mice could 
explain the lower numbers of cDC precursors observed 
in the BM and also contribute to the inefficient in vitro 
generation of BMDCs. To test the latter hypothesis, 
different concentrations of recombinant mouse TNF-α 
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were added to the cultures of differentiating Sirt6KO 
BMDCs and the frequency of CD11c
+
 cells was 
analyzed and compared to that of WT BMDCs. 
Supplementation with concentrations of TNF-α that 
mimicked those found in the supernatants of WT 
BMDCs (0.5-1 ng/ml) was indeed found to increase the 
frequency of CD11c
+
 cells in Sirt6KO BMs (p<0.05; 
n=9 for each genotype) without, however, fully 
reverting the original phenotype (Figure 1G).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, higher TNF-α concentrations (10-20 
ng/ml) not only failed to increase the frequency of 
CD11c
+
 BMDCs in cultured Sirt6KO BMs, but they 
even reduced it (p<0.01 for 10 ng/ml TNF-α, and 
p<0.001 for 20 ng/ml TNF-α; n=6 for each genotype). 
Thus, overall, these experiments indicated that Sirt6 
promotes BMDC differentiation in a way that is 
partially dependent on its ability to promote TNF-α 
secretion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Sirt6 regulates the generation of cDCs in vivo and in vitro. (A, B) WT or Sirt6KO BM cells were cultured with GM‐
CSF and  their ability  to generate CD11c+ cells was analyzed at day 3, 5  ,7 by  flow cytometry.  (A) The percentage of CD11c+ cells
within cultures of Sirt6KO BMs  (day 7) was normalized  to  that of WT CD11c+ cells. Results are presented are means ± SEM of 6
separate experiments, n=13 for each genotype; ***: p<0.001. (B) one representative experiment out of two is presented. (C‐E) BM
cells from WT and Sirt6KO mice were analyzed by flow cytometry for the frequency of cDC precursors (pre‐cDCs, CD11c+MHCII‐),
pDCs, monocyte/macrophage  subsets, mature granulocytes and of BM progenitors of different  lineages.  (C) one  representative
experiment  out  of  six  is  presented;  (D,  E)  results  are  presented  are means  ±  SEM  of  fifteen  and  six  separate  experiments,
respectively, n=6‐15 for each genotype; *: p<0.05; **: p<0.01; n.s.: not significant. (F) TNF‐α concentration in the supernatants of
WT and Sirt6KO BMDCs (harvested at day 6) were determined by ELISA. Results are means ± SEM of three separate experiments,
n=10  for  each  genotype;  *:  p<0.05.  (G) WT  and  Sirt6KO  BM  cells were  cultured with GM‐SCF with  or without  addition  of  the
indicated concentrations of TNF‐α. CD11c+ cells were quantified at day 6 by flow cytometry. One representative experiment out of
six is presented, n=6‐9 for each genotype. 
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Sirt6 deficiency prevents the spontaneous 
maturation of in vitro generated BMDCs in a 
partially TNF-α dependent fashion 
 
Subsequent experiments were directed at defining the 
phenotypic and functional features of Sirt6KO BMDCs, 
starting from their degree of maturation. Indeed, 
BMDCs generated in vitro with GM-CSF undergo a 
spontaneous maturation process that is characterized by 
the expression of different levels of MHCII and 
costimulatory molecules CD80 (B7.1) and CD86 
(B7.2), depending on the degree of maturation reached 
[21]. High levels of MHCII and of CD80 and CD86 are 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
considered hallmarks of mature BMDCs, while 
immature BMDCs and BMDC precursors are 
characterized by low and no MHCII expression, 
respectively [21]. As compared to WT BMDCs, 
Sirt6KO BMDCs were found to express lower levels of 
MHCII, CD86 (Figure 2A) and CD80 (see below), 
while class I MHC expression was not affected (data 
not shown). When using MHCII and CD86 expression 
to distinguish between mature BMDCs 
(CD11c+/MHCIIhigh/CD86high), immature BMDCs 
(CD11c+/MHCIIlow/CD86low/neg), and BMDC precursors 
(CD11c+/MHCII-/CD86-), in Sirt6KO BMs cultured in 
the presence of GM-CSF, we detected a clear decrease 
Figure 2. Sirt6 deletion hampers the spontaneous maturation of BMDCs. (A, B) BM cells from WT and Sirt6KO mice
were cultured for 6 days with 20 ng/ml GM‐CSF. At day 6, cells were re‐seeded in the presence of 5 ng/ml GM‐CSF and CD86,
MHCII, and CD11c expression was determined at day 7 by flow cytometry. (A, B) One representative experiment out of eight is
presented.  (B)  lower  inset,  results are means ± SEM of eight  separate experiments; n=13  for each genotype; *: p<0.05; **:
p<0.01. (C) WT and Sirt6KO BMDCs harvested at day 6 of culture were re‐seeded with TNF‐α at the indicated concentrations. 24
h  later, BMDCs were harvested and analyzed by flow cytometry. One representative experiment out of five  is presented (n=8
for each genotype).  
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in the representation of both mature and immature 
BMDCs. This effect was accompanied by an 
accumulation of BMDC precursors in Sirt6KO BM 
cultures as compared to cultures of WT BM (Figure 
2B). Thus, these data indicate that Sirt6 deletion impairs 
the spontaneous maturation process that BMDCs 
normally undergo. 
 
The role of TNF-α in cDC differentiation and 
maturation has been largely described, both in mice and 
humans [21, 26]. To test whether the impaired 
differentiation/maturation of Sirt6KO BMDCs would 
reflect their reduced ability to secrete TNF-α  (Figure 1F), 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 we added different amounts of this cytokine to the cell 
cultures at 6 day and evaluated the maturation achieved 
by Sirt6KO and WT BMDCs 48 h later. As shown in 
Figure 2C, adding TNF-α at concentrations that 
mimicked those found in cultures from WT BMDCs 
(i.e. 1 ng/ml) was not sufficient to increase the 
frequency of Sirt6KO mature BMDCs to the control 
levels (WT mature BMDC vs. Sirt6KO mature BMDC: 
p<0.01; n=8 for each genotype). However, higher TNF-
α concentrations did increase the representation of 
mature BMDCs to the levels observed within WT 
BMDCs (p=0.49 for WT vs. Sirt6KO BMDCs plus 10 
ng/ml TNF-α, and  p=0.32 for WT vs. Sirt6KO BMDCs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  3.  In  vitro  generated  Sirt6KO  BMDCs  show  increased  endocytic  activity  and  impaired  allostimulatory
capacity. (A, B) WT and Sirt6KO BMDCs were harvested at day 7 and incubated with dextran‐FITC for 30 min at 37°C or at 4°C.
Thereafter,  cells were  stained  for CD11c and  finally analyzed by  flow  cytometry.  (A) Gating was done on CD11c+  cells; one
representative  experiment  out  of  six  is  presented.  (B)  Dextran‐FITC+/CD11c+  Sirt6KO  BMDCs  were  enumerated  and  their
frequency was normalized to that of dextran‐FITC+/CD11c+ WT BMDCs. Results are means ± SEM of six separate experiments,
n=6  for each genotype.  (C) purified allogeneic  (BALB‐c) CD4+ splenocytes  (responders) were stained with CFSE and  incubated
with  5  μg/ml  phythoemagglutinin  (PHA)  or  with  sorted, WT  or  Sirt6KO,  CD11c+MHCII+  BMDCs  at  the  indicated  S:R  ratios.
Proliferation of alive  (propidium‐iodide negative) CD3+CD4+CD11c‐ cells was evaluated by carboxyfluorescein succinimidyl ester
(CFSE) dilution after a 5‐day incubation. One representative experiment out of three is presented, n=4 for each genotype. 
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plus 20 ng/ml TNF-α; n=8 for each genotype). 1 ng/ml 
and 10 ng/ml TNF-α failed to increase the frequency of 
immature (CD11c+/MHCIIlow/CD86low/neg) Sirt6KO 
BMDCs to the control level (p=0,0373 and p=0.0151 
vs. WT immature BMDCs, respectively), while TNF-α 
at a concentration of 20 ng/ml even further reduced the 
representation of immature BMDCs in cultured Sirt6KO 
BM cells (p<0.001). Thus, overall, the defective 
spontaneous maturation that Sirt6KO BMDCs exhibit 
appears to partially reflect their reduced production of 
TNF-α. However, the contribution of other mechanisms 
cannot be excluded. 
 
cDC maturation is typically accompanied by a loss in 
their ability to capture antigens and by an increase in 
their immunostimulatory capacity [26]. Consistent with 
a highly immature phenotype, Sirt6KO BMDCs were 
found to exhibit an increased endocytic activity 
compared to the WT BMDCs, as detected by 
monitoring FITC-dextran uptake (Figure 3A, B). A 
more detailed analysis demonstrated that the Sirt6KO 
BMDCs that exhibited increased dextran uptake were 
primarily the CD11+/MHCII- precursors and, 
interestingly, also the mature (CD11+/MHCIIhigh) 
BMDCs, while immature (CD11+/MHCIIlow) Sirt6KO 
BMDCs essentially presented an uptake that was 
comparable to the WT BMDCs (Supplementary Figure 
1). Finally, in line with a less mature phenotype, 
Sirt6KO BMDCs also showed a reduced ability to 
simulate allogeneic lymphocyte proliferation in mixed 
leukocyte reaction (MLR;, Figure 3C; p<0.05 at a 
stimulator-to-responder - S:R - ratio of 1:10; n=4 for 
each genotype).  
 
Sirt6 contributes to BMDC maturation in response 
to Toll-like receptor ligands  
 
The initiation of adaptive immune responses is critically 
dependent on cDC maturation. Complete cDC 
maturation is typically triggered by conserved 
molecular patterns that are expressed by infectious 
agents and that bind Toll-like receptors (TLRs) on 
immune cells, or by pro-inflammatory cytokines [1, 2]. 
To test the consequences of the absence of Sirt6 on 
BMDC maturation in response to TLR ligands, we 
stimulated WT and Sirt6KO BMDCs with 
lipopolysaccharide (LPS) or CpG oligonucleotide 
(CpG) and then monitored the expression of MHCII, 
CD80, CD86, as well as of CD40, a key costimulatory 
molecule involved in cDC licensing by activated T cells 
[27]. As previously mentioned, in the absence of 
stimuli, Sirt6KO BMDCs were found to express lower 
levels of MHCII, CD80 and CD86 as compared to WT 
BMDCs, while CD40 expression was essentially 
undetectable in either type of BMDCs (WT and 
Sirt6KO) (Figure 4A). Following stimulation with LPS 
or CpG, both WT and Sirt6KO BMDCs upregulated all 
of the surface markers. Nevertheless, MHCII, CD80, 
CD86, and CD40 expression on Sirt6KO BMDCs was 
consistently lower as compared to the WT BMDCs 
regardless of the stimulus that was applied. Prolonging 
the stimulation or increasing the concentration of the 
stimuli failed to abrogate this difference (data not 
shown). Notably, quantitative PCR (qPCR) failed to 
identify significant differences between WT and 
Sirt6KO BMDCs in terms of expression of Tlr4 (LPS 
receptor) and Tlr9 (CpG receptor), as well as of Tlr2, 
Tlr3, and Tlr7 (Supplementary Figure 2A), indicating 
that the defective maturation of Sirt6KO BMDCs in 
response to the TLR ligands is not due to reduced 
expression of the TLRs themselves. Overall, these data 
clearly indicate that Sirt6 takes part in final maturation 
of BMDCs in response to TLR ligands and that Sirt6 
deficiency results in a lower expression of MHCII and 
of costimulatory molecules on maturing cDCs. 
 
Mature BMDCs also upregulate the CC-chemokine 
receptor 7 (CCR7), which, in turn, allows cDC 
migration to the lymph nodes via afferent lymphatics 
[1]. Specifically, CCR7-dependet migration occurs in 
response to ligands such as CCL21. Once again, 
consistent with a lower degree of maturation, both 
unstimulated and LPS- or CpG-stimulated Sirt6KO 
BMDCs exhibited reduced CCR7 expression as 
compared to the WT BMDCs (Figure 4B, C). 
Furthermore, in line with a reduced CCR7 expression, 
CCL21-driven migration of LPS-stimulated Sirt6KO 
BMDCs was found to be defective compared to the 
control WT BMDCs (Figure 4D). A similar impairment 
in CCL21-driven migration was also observed in 
Sirt6KO BMDCs that had been stimulated with CpG or 
with polyinosinic:polycytidylic acid (poly:IC; data not 
shown). 
 
Sirt6 deletion skews cytokine production by BMDCs 
 
Mature cDCs normally secrete large amounts of 
cytokines which, in turn, contribute to the overall 
orchestration of an effective immune response [1, 2]. 
We used intracellular cytokine staining and ELISAs to 
monitor the effects of Sirt6 deficiency on the ability of 
BMDCs to produce TNF-α, IL-6 and IL-12. Using these 
approaches, in Sirt6KO BMDCs, we found a general 
reduction in the expression of most of the cytokines 
analyzed. In unstimulated Sirt6KO BMDCs, there was a 
decrease in the percentage of CD11c+CD86+ TNF-α-
producing cells (Figure 5A, Supplementary Figure 3A) 
and TNF-α concentration in cell supernatants was also 
consistently reduced (919 ± 154.6 pg/ml in WT 
BMDCs, n=7; 523 pg/ml ± 76.6 pg/ml in Sirt6KO 
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BMDCs, n=10; p<0.05). Interestingly, in the absence of 
stimuli, the expression of IL-6 in Sirt6KO BMDCs was 
significantly increased both  in  terms  of  frequency  of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD11c+CD86+ IL-6-producing cells (Figure 5B, 
Supplementary Figure 3B) and of IL-6 concentration in 
cell supernatants (248 pg/ml ± 56.8 in WT BMDCs, 
n=3; 506,7 ± 51,8 pg/ml in Sirt6KO BMDCs, n=3; 
p<0.05). However, upon BMDC stimulation with TLR 
ligands, we observed different and stimulus-dependent 
cytokine expression patterns. In response to a 24-h 
stimulation with LPS, there was a higher frequency of 
CD11c+CD86+ TNF-α-producing cells among the 
Sirt6KO BMDCs as compared with the controls (Figure 
5A, Supplementary Figure 3A), which was 
accompanied by a consistent increase in TNF-α 
secretion (Figure 5D). The same effect was observed  in  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
response to the TLR2 ligand zymosan (Zym; TNF-α 
concentrations in the supernatants of Zym-stimulated 
BMDCs were 56.9 ± 21.6 ng/ml for WT cells, n=5; and 
91.4 ± 14.5 ng/ml for Sirt6KO cells, n=5; p<0.05). As 
already documented elsewhere [15, 16], CpG was less 
effective at increasing the frequency of CD11c+CD86+ 
TNF-α-producing cells (Figure 5A, Supplementary 
Figure 3A) and at stimulating TNF-α secretion (Figure 
5D) in Sirt6KO BMDCs than it was in WT BMDCs. 
Notably, a reduced TNF-α production by Sirt6KO 
Figure 4. Sirt6KO BMDCs show impaired maturation and CCR7 expression in response to TLR ligands. (A‐C) WT and
Sirt6KO  BMDCs were  harvested  at  day  7  and  stimulated with  or without  LPS  or with  CpG  for  24  h.  Thereafter,  cells were
harvested, washed, and MHCII, CD86, CD80, CD40 and CCR7 expression on CD11c+ cells was analyzed by flow cytometry. (A, B)
One  representative  experiment  out  of  ten  (A)  or  out  of  four  (B)  is  presented  (n=4‐21  for  each  genotype).  (C)  CCR7 mean
fluorescence intensity (MFI) was normalized to that of WT BMDCs. Results are means ± SEM of four separate experiments, n=11
for  each  genotype;  ***:  p<0.001.  (D) WT  and  Sirt6KO  BMDCs were  harvested  at  day  7  and  stimulated  for  24  h with  LPS.
Thereafter, cell migration to CCL21 was evaluated. The percentage of Sirt6KO BMDCs that had migrated was normalized to that
of WT BMDCs. Results are means ± SEM of three separate experiments, n=4 for each genotype; *: p<0.05. 
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BMDCs appeared to be recorded in response to CpG, 
but not to ligands of other endosomal TLRs: stimulating 
TLR7/8 with R848 resulted in higher frequencies of 
CD11c+CD86+ TNF-α producing cells among the 
Sirt6KO BMDCs (80.5 ± 1,7% TNF-α-producing WT 
BMDCs, n=9; 85.0 ± 1.2% TNF-α-producing Sirt6KO 
BMDCs, n=9; p<0.05) and in a consistent increase in 
TNF-α secretion into cell supernatants by the latter as 
compared to the control BMDCs (Figure 5D). Similarly, 
the frequency of CD11c+CD86+ TNF-α-producing 
BMDCs in response to the TLR3 ligand, polyI:C, was 
higher among the Sirt6KO BMDCs as compared to the 
WT BMDCs (92% ± 1,6% vs. 84 ± 1.5%, respectively; 
p<0.05) and a similar pattern of TNF-α secretion was 
observed in cell supernatants (Figure 5D). As 
previously anticipated, the reduced ability of CpG to 
stimulate TNF-α (as well as IL-6, see below) production 
in Sirt6KO BMDCs did not reflect a reduced expression 
of its receptor (Tlr9) (Supplementary Figure 2A) and 
neither was it associated with an impaired expression of 
Unc93b1,  a   protein  involved  in   the  trafficking  and  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
proper function of endosomal TLRs (Supplementary 
Figure 2B) [28, 29]. Incubating the BMDCs for 
shorterperiods of time (2h, 4h, 6h) or increasing the 
concentration of TLR ligands up to 10 fold essentially 
did not modify these differences (data not shown). The 
effect of Sirt6 deletion on the frequency of 
CD11c+CD86+ IL-6-producing BMDCs and on IL-6 
secretion into cell supernatants in response to the 
different TLR ligands resembled that observed for TNF-α 
(Figure 5B, Supplementary Figure 3B and data not 
shown). On the other hand, IL-12 exhibited a completely 
different pattern of expression between WT and Sirt6KO 
BMDCs. Namely, in absence of Sirt6, we detected a 
strong reduction in the frequency of IL-12p70-producing 
BMDCs, as well as in IL-12 concentration in BMDCs 
supernatants, in response to all of the TLR ligands tested 
(Figure 5C, E, Supplementary Figure 3C). These data 
highlight for the first time a role for Sirt6 in the control of 
IL-12 production and strengthen the notion that the 
contribution of Sirt6 to the regulation of cytokine 
expression is both stimulus- and cytokine-dependent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Sirt6 deletion skews cytokine production in BMDCs. (A‐E) WT and Sirt6KO BMDCs were
harvested  at  day  8  and  stimulated  for  24  h  with  or  without  different  TLR  ligands.  (A‐C)  Cells  were
harvested, stained for CD11c, CD86 and intracellular TNF‐α, IL‐6 or IL‐12. CD11c+CD86+ TNF‐α‐, IL‐6‐, or IL‐
12‐producing cells were quantified by flow cytometry. Results are means ± SEM of three‐to‐five separate
experiments, n=3‐10 for each genotype. In (D, E), cytokine secretion into cell supernatants was measured
by ELISA. Results are means ± SEM of 3‐10 separate experiments; *: p<0.05; n.s.: not significant.  
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SIRT6 inhibition prevents moDC differentiation 
 
Having established that Sirt6 plays a critical role in 
BMDC differentiation, maturation and function, we 
aimed at assessing whether such a role would be 
present in human cDCs, too. moDCs are a broadly 
used model of human cDCs [26]. Making use of S6, a 
SIRT6 inhibitor that our group has recently identified 
(compound 5 in the original study [23]), we evaluated 
the effects of SIRT6 blockage on moDC 
differentiation and immunostimulatory capacity. In 
line with the effects of Sirt6 deletion in BMDCs, 
inhibiting SIRT6 in differentiating moDCs was found 
to prevent both the downregulation of CD14 and the 
expression of CD1a which typically occur in response 
to GM-CSF and IL-4 (Figure 6A, B) [26], with the 
strongest effects observed at the highest S6 
concentration. Consistent with the ability of S6 to 
block monocyte differentiation into moDCs, cells that 
had been cultured in the presence of the SIRT6 
inhibitor also exhibited a markedly reduced capacity to 
stimulate the proliferation of allogeneic lymphocytes 
in MLR (Figure 6B). Thus, these data confirmed that 
SIRT6 plays a crucial role in ensuring proper 
differentiation and function of human cDCs, too. 
  
DISCUSSION 
 
In this work, we addressed for the first time the role of 
Sirt6 in lineage determination, maturation and function 
of cDCs, defining a new function for Sirt6 within the 
immune system that complements those connected to 
the control of cytokine expression already described 
elsewhere [13, 15-18]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Our study reveals that Sirt6 promotes cDC 
differentiation and maturation at different levels. In the 
first place, we were able to demonstrate reduced 
frequencies of CMPs and of cDC precursors in the BM 
of Sirt6KO mice compared to WT animals, indicating 
that the role of Sirt6 in cDC generation is relevant in 
vivo. Notably, pDCs were found to be similarly 
represented in WT and Sirt6KO BMs, indicating a 
specific role of Sirt6 in the cDC lineage. MEP were also 
expressed at lower frequencies in BMs from Sirt6KO 
animals, while differentiation into the granulocyte-
macrophage lineage appeared to be enhanced (as judged 
based on the frequency of GMP, granulocytes and 
monocytes/macrophages in Sirt6KO BMs).  
 
Our data clearly indicate that in vitro BMDC generation 
is inefficient when Sirt6 is lacking. Such impairment in 
BMDC generation, as well as, likely, the reduced 
representation of cDC precursors in Sirt6KO BMs could 
be explained by the reduced availability of TNF-α, a 
cytokine that contributes to BMDC differentiation and 
maturation [2, 24, 25] and whose secretion is 
compromised in Sirt6KO cells [13, 15, 16] (including 
BM cells). Notably, the increased myelogranulocytic 
hematopoiesis found in Sirt6KO mice is also in line 
with a lack of TNF-α and consequent removal of TNF-
α-mediated inhibition of colony-forming units-
granulocyte [30]. Supplementation of Sirt6KO BMDC 
cultures with concentrations of TNF-α that were similar 
to those found in WT BMDCs (0.5-1 ng/ml) did 
increase the frequency of conventional CD11c+ cells 
recovered. However, the rescue effect we observed was 
partial. In fact, higher concentrations of TNF-α (10-20 
ng/ml) even reduced the recovery  of  Sirt6KO  BMDCs,  
Figure 6. SIRT6 inhibition prevents moDC differentiation. (A‐C) Human adherent PBMCs were cultured with GM‐CSF and IL‐4 
for 6 days in the presence of either S6 (at the indicated concentrations) or vehicle DMSO. Thereafter, cells were harvested, washed 
and analyzed by flow cytometry for CD14 and CD1a expression or utilized as stimulators in MLR. (A) One representative experiment 
out of five is presented. (B, C) Results are means ± SEM of those obtained with five different donors. *: p<0.05; ***: p<0.001.  
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which could reflect the tendency of high amounts of 
TNF-α to switch CD34+ progenitor differentiation 
towards the macrophage lineage [31]. The immuno-
phenotype of these BM cultures (CD11c-
CD11b+LyC+LyG-, data not shown) indeed supports this 
notion. On the one hand, these results support a role for 
a reduced availability of TNF-α in the less efficient 
generation of BMDCs that was typically observed with 
Sirt6KO BMs [24, 25]. On the other hand, the 
impossibility to fully revert this phenotype suggests the 
involvement of additional mechanisms. For instance, 
IL-6 was shown to inhibit cDC differentiation and 
maturation in vivo in mice [32]. Among the different 
potential cellular sources of this cytokine, mesenchymal 
stem cells were reported to produce high IL-6 amounts, 
thereby preventing cDC differentiation [33]. We 
observed increased IL-6 production in mesenchymal 
stem cells generated from Sirt6KO mice (D.L., 
unpublished data). In addition, Sirt6KO BMDCs (both 
in baseline conditions and, even more, in response to 
TLR ligands) were found to produce high quantities of 
this cytokine. Thus, increased IL-6 secretion by cDC 
precursors and by cells from the microenvironment (i.e. 
mesenchymal stem cells) could both contribute to 
reduce cDC representation in the BM of Sirt6KO mice 
and to reduce the yield of BMDCs generated in vitro.  
   
In addition to a role for Sirt6 in cDC differentiation, our 
data also indicate a key function for this deacetylase in 
cDC maturation. Namely, both the spontaneous 
maturation process that BMDCs cultured with GM-CSF 
undergo and BMDC maturation that occurs in response 
to TLR ligands were defective in the absence of Sirt6. 
Sirt6KO BMDCs cultured in the absence of TLR 
ligands exhibited a reduction in the frequency of both 
immature CD11c+MHCIIlowCD86low/neg and mature 
CD11c+MHCIIhighCD86high BMDCs, and a preferential 
accumulation of immature CD11c+MHCII-CD86- 
BMDC precursors. Notably, a more immature 
phenotype of the Sirt6KO BMDCs was confirmed by an 
increased propensity to perform endocytosis (a property 
that is typical of immature cDCs and that is 
downregulated during maturation) and by a reduced 
immunostimulatory capacity in MLR [1, 26]. Given the 
reduced TNF-α concentrations detected in Sirt6KO 
BMDC cultures and the established role of this cytokine 
in promoting cDC maturation [1, 26], we assessed the 
effect of TNF-α supplementation on this phenotype. A 
restoration of the frequency of mature BMDCs could be 
achieved at the highest TNF-α concentrations used (10-
20 ng/ml), while the same conditions essentially failed 
to lead to a representation of immature BMDCs within 
Sirt6KO cell preparations that would be comparable 
with the one observed in WT BMDCs. These data 
suggest that Sirt6’s ability to regulate TNF-α secretion 
is involved in the final maturation of BMDCs. 
However, again, the contribution of additional 
mechanisms cannot be excluded. TLR ligands, such as 
LPS and CpG, were used to test the ability of Sirt6KO 
BMDCs to undergo a full maturation [1]. These stimuli 
did induce MHCII, CD80, CD86, and CD40 
upregulation both in WT and in Sirt6KO cDC. 
However, the expression of these markers was typically 
much lower in Sirt6KO BMDCs compared to WT 
BMDCs. Notably, CCR7 expression in Sirt6KO 
BMDCs was also markedly reduced, both in baseline 
conditions and after stimulation with TLR ligands. 
Consistently, CCL21-induced migration was reduced in 
Sirt6-deficient BMDCs. These observations are relevant 
as they show for the first time a contribution of Sirt6 to 
the expression of costimulatory molecules, including 
CD40, and of CCR7 in cDCs, as well as, consequently, 
to CCL21-driven cDC migration. 
 
Cytokine expression by cDCs is typically fine-tuned 
and is essential for the priming of T cell responses, but 
also for the termination of inflammatory responses and 
for self-tolerance maintenance [1]. Skewed cytokine 
release by cDCs may result in immune defects and/or 
autoimmunity. Our study highlights differential effects 
of Sirt6 deletion on cytokine production by BMDCs. In 
baseline conditions (in the absence of TLR ligands), 
Sirt6 depletion was found to result in a reduced 
expression of TNF-α and IL-12, while IL-6 production 
was increased. On the other hand, Sirt6KO BMDCs 
showed an increase propensity to secrete TNF-α and IL-
6 in response to TLR ligands, with the exception of 
CpG, which binds TLR9 and that was previously shown 
to stimulate the production of lower amounts of 
cytokines by Sirt6KO cells [15, 16]. Higher TNF-α and 
IL-6 production in response to TLR ligands in Sirt6KO 
cells could reflect increased NF-κB and AP-1 activity in 
these cells, as suggested by previous reports [18, 19]. 
Notably, in the case of TNF-α   production in response 
to TLR ligands, the latter mechanisms appear to prevail 
on Sirt6’s ability to promote the secretion of this 
cytokine by direct deacylation [14], which, in itself, 
would rather explain a reduction, instead of an increase, 
in TNF-α secretion by Sirt6KO BMDCs (which indeed 
occurs, but only in unstimulated BMDCs). On the other 
hand, the molecular basis for the apparently selective 
role of Sirt6 in mediating TLR9-dependent cytokine 
production remains to be defined. The qPCRs we 
performed to monitor the levels of Tlr9 and of 
Unc93b1, a protein with a key role in the trafficking of 
endosomal TLRs [28, 29], failed to detect significant 
differences between Sirt6KO and WT BMDCs. 
Moreover, Sirt6KO BMDCs responded with an 
increased TNF-α and IL-6 production in response to 
TLR ligands that bind other TLRs localized within the 
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endosomes, such as TLR3 and TLR7/8, which 
essentially rules out a major defect in the uptake of TLR 
ligands due to Sirt6 deletion. In line with this notion, 
endocytosis was rather increased, instead of reduced, in 
Sirt6KO BMDCs. Interestingly, IL-12 production was 
found to be subjected to a completely different 
regulation by Sirt6, in that, in Sirt6KO BMDCs, it was 
uniformly defective in response to all of the stimuli 
used. These data demonstrate for the first time a crucial 
role for Sirt6 in IL-12 regulation. Moreover, overall, 
they confirm that the effects of Sirt6 on cytokine 
production can be very different, depending on the 
cytokine and on the type of stimulus that cells 
encounter.  
 
Here we also took advantage of the availability of a 
recently identified SIRT6 inhibitor (S6) [23] to study 
the role of SIRT6 in human moDCs. Using this tool, we 
were able to find a striking effect of SIRT6 inhibition in 
this cDC model, in that monocyte differentiation into 
moDCs was virtually completely blocked by the SIRT6 
inhibitor as judged based on CD14 downregulation and 
CD1a upregulation, both of which did not occur when 
SIRT6 was inhibited. Consistent with a major defect in 
moDC differentiation, cells generated in the presence of 
the SIRT6 inhibitor failed to stimulate allogeneic 
lymphocytes in MLR. Thus, these data essentially 
confirm that SIRT6 plays a critical role in human cDC 
differentiation and function, too.  
 
In aged humans, lower percentages of circulating cDCs 
are found in the peripheral blood [5] and aged cDCs 
lose their ability to migrate to the lymph nodes and to 
prime CD4+ and CD8+ T cells [6]. In addition, 
consistent with the patterns of circulating cytokines 
found in elderly and that were shown contribute to 
frailty, morbidity and mortality [34, 35], cDCs from 
aged subjects typically secrete excessive amounts of IL-
6 and TNF-α [4, 6]. Given that Sirt6 expression and 
function probably decrease during aging [10-12], it is 
appealing to speculate that such a reduction in Sirt6 
activity may contribute to determine these features of 
aged cDCs, and, thereby, play a causative role in 
immunosenescence [36].  
 
In conclusion, we propose a key role for Sirt6 in cDC 
differentiation, maturation and function. We show that 
Sirt6 controls cDC lineage commitment in vivo and in 
vitro, acting very early during myeloid differentiation in 
a way which is only partially dependent on its ability to 
promote TNF-α production. In fact, our data strongly 
suggest that other mechanisms in addition to TNF-α 
secretion, including, possibly, Sirt6’s activity as an 
epigenetic regulator of NF-κB [19, 37], are likely to 
contribute to its roles in cDCs. Our data clearly indicate 
a role for Sirt6 in the expression of costimulatory 
molecules, including CD40, as well as in the production 
of IL-12. Besides, we also provide evidences for a role 
for this deacetylase in regulating CCR7 expression and, 
as a result, CCL21-induced cDC migration. Overall, 
Sirt6 emerges from this study as a master regulator of 
cDC biology. This work opens new scenarios for future 
investigations of the complex epigenetic mechanisms 
involved in the regulation of cDC function.   
 
MATERIALS AND METHODS 
 
Animals and hematology. 129/Sv Sirt6+/- mice (2-8 
month old) were bred weekly to generate WT and 
Sirt6KO mice. Mice were kept in temperature- and 
light-controlled conditions and fed ad libitum. All 
experiments were performed in accordance with the 
relevant laws and institutional guidelines for animal 
care and use following approval by the Institutional 
Animal Care and Use Committee of the IRCCS A.O.U. 
San Martino-IST (Genoa, Italy). In order to avoid the 
potentially confounding effects of the acute metabolic 
syndrome that affects these mice in their fourth week of 
life, we performed all the immunological tests and 
isolated bone marrow (see below) using 16-18-days old 
Sirt6KO mice (or aged-matched WT littermates). At 
this age, no difference in the percentage of apoptotic 
immune cells between WT and Sirt6KO mice could be 
detected ex vivo by standard Annexin-V/propidium 
iodide staining and flow cytometry analysis of cells 
isolated from the thymus (data not shown). For blood 
counts determination, ~100µl blood were collected in 
EDTA coated tubes and blood counts were determined 
using an automated analyser (scil Vet abc Plus).  
 
BMDC and moDC generation and stimulation. 
Following mouse BM harvest by flushing of tibiae and 
femurs, BMDCs were generated by culturing total bone 
marrow cells at 1 x 106cells/ml density in RPMI-1640 
supplemented with 10% Hyclone® serum, 100 U/ml 
penicillin-streptomycin, 5 x 10-2 mM β-mercapto-
ethanol, 1% not essential amino acids, 1% sodium 
pyruvate, containing 20 ng/ml GM-CSF (Carlsbad, CA, 
USA) [21, 22]. At day 6, cells were harvested and 
reseeded in fresh medium in presence of 5 ng/ml GM-
CSF. BMDC differentiation was detected by monitoring 
CD11c expression. BMDC maturation was induced by 
stimulation with the following TLR ligands: 100 ng/ml 
LPS [Sigma Aldrich, 0111:B4 serotype; TLR4 ligand], 
1 µg/ml CpG (1826; Tib Molbiol; TLR9 ligand), 1 
µg/ml R848 (Enzo Life Sciences; TLR7/TLR8 ligand); 
50 µg/ml Zym (Sigma Aldrich; TLR2, dectin 1, dectin 2 
ligand), or 25 µg/ml polyI:C (Enzo Life Sciences; TLR3 
ligand). For the detection of cytokine concentrations in 
cell supernatant, 2 x 105 BMDCs were seeded in 96-
  
www.impactaging.com                     44                                     AGING, January 2016, Vol. 8 No.1
wells and stimulated for 24 h with or without TLR 
ligands (see above). For immunophenotyping and 
cytokine detection by intracellular staining, BMDCs 
were harvested at day 8 of culture and 3 x 106 BMDCs 
were plated in 12-well plates and stimulated with or 
without TLR ligands at the previously mentioned 
concentrations in presence of 1 µg/ml Brefeldin A 
(BFA, Sigma Aldrich). In the rescue experiments with 
TNF-α, total BM cells or BMDCs harvested at day 6 of 
culture were cultured in presence of increasing 
concentrations (0.5, 1, 10, or 20 ng/ml) of mouse 
recombinant TNF-α (Miltenyi Biotech GmbH). 
 
moDCs were generated from adherent monocytes as 
described previously [26, 38]. In brief, buffy coat 
preparations from healthy volunteers were obtained 
from the blood bank of the IRCCS A.O.U. San Martino-
IST (Genoa, Italy). Peripheral blood mononuclear cells 
(PBMCs) were isolated by Ficoll-Paque (Biochrom) 
density gradient centrifugation. Cells were resuspended 
in serum-free X-VIVO 20 medium (Cambrex) and 
seeded (1 × 107 cells/well) for 2 h in 6-well plates at 
37°C. Afterward, non-adherent cells were removed by 
extensive washing with PBS (Life Technologies). 
moDCs were generated by culturing the adherent 
monocytes in RPMI-based medium supplemented with 
100 ng/ml GM-CSF (molgramostim, Leucomax) and 20 
ng/ml human recombinant IL-4 (R&D) in the presence 
or absence of S6 [compound 5 from [23]; purchased 
from Asinex] at the indicated concentrations, or of 
vehicle DMSO. At day 6 of culture, cells were 
harvested for subsequent immuno-phenotyping and 
used as stimulators in MLR. 
 
Immunostaining and flow cytometry. The monoclonal 
antibodies (mAbs) that were used for the 
immunophenotyping and for intracellular cytokine 
staining in BMDCs were the following: CD11c (clone 
G418), MHCII (IA/IE, clone M5/114.15.2), CD86 (clone 
GL1), CD80 (clone 16-10A1), CD40 FITC (clone 3/23), 
CCR7 (CD197, clone 4B12), TNF-α (clone MP6-
XT22), IL-6 (clone MP5-20F3) were all from Biolegend 
(CA, USA). Anti-MHCI (clone 28.8.6 ), and anti-IL-12 
(p40/p70, clone C15.6) were from Becton Dickinson 
(BD; NJ, USA). The mAbs that were used for the ex 
vivo immunophenotyping of BM cells and of BMDCs 
were the following: Ter119 (clone TER119, BD), CD19 
(clone 1D3, BD), CD3 (clone 17A2 Biolegend), CD8a 
(clone 53-6.7, Biologend), CD4 (clone GK1.5, 
Biolegend), Gr1 (clone RB6-8C5, Biolegend), B220 
(clone RA3-6B2, Biolegend), CD16/CD32 (clone 
2.4G2, BD), CD34 (clone HM34, Biolegend), CD117 
(c-kit, clone ACK2, Life Technologies), Sca-1 (clone 
D7, Biolegend), CD127 (IL7R clone LG.7F9, 
Ebioscience), Ly6C (clone HK1-4, Biolegend), Ly6G 
(clone 1A8, Miltenyi Biotech), CD11b (clone M1/70, 
Biolegend), PDCA1 (clone JF05-1C2.4.1, Miltenyi 
Biotech). Within BM cells, the combined expression of 
Gr1 and CD11b was used to discriminate between 
granulocytes (Gr1+CD11b+) and the mono/macrophage 
subpopulation (Gr1-CD11b+). pDCs were identified as 
CD11cintCD11b-PDCA1+B220+ cells. CD34+ 
progenitors were characterized as lin-Sca1-CD117+. A 
subsequent analysis of the combined expression of 
CD16/CD32 and CD34 was performed to discriminate 
between granulocyte/monocyte progenitors (GMP, 
CD16/CD32highCD34+), common myeloid progenitors 
(CMP, CD16/CD32lowCD34+) and megakaryocyte/ 
erytrocyte progenitors (MEP, CD16/CD32lowCD34-). 
Common lymphoid progenitors (CLP) were identified 
as lin-Sca1-CD117+CD127+ cells. Cell were stained in 
FACS buffer [PBS with 1% fetal calf serum (FCS)] for 
15 min at 4ºC, washed and a minimum of 30.000 
cells/sample were analyzed by flow cytometry. 
Intracellular cytokine detection was done according to 
the instructions of the manufacturers. In brief, BMDCs 
were stained with mAbs against surface markers, fixed 
and permeabilized using cytofix/cytoperm kit™ (BD). 
Cells were subsequently incubated with mAbs for 
cytokines and, following extensive washings, they were 
analyzed by flow cytometry. Human moDC 
immunophenotyping was performed with mAbs against 
CD14 (BD) and CD1a (Dako). All the flow cytometry 
analyses were done on a FACScanto™ cytometer and 
analyzed using Flow-Jo_V10 software (Tree Star) or 
CellQuest.  
 
Dextran uptake detection. Quantitative analysis of 
endocytosis was performed as described elsewhere [39]. 
In brief, 2 x 105 BMDCs harvested at day 7 of culture 
were incubated with FITC-dextran (MW 40,000, 
Invitrogen) for 30 min at 37°C or at 4°C. Endocytosis 
was blocked by 2 washes in ice-cold PBS with 1% FCS. 
Cells were then stained for CD11c alone or in 
combination with MHCII and subsequently analyzed by 
flow cytometry with a FACScanto™ cytometer. 
 
ELISAs. TNF-α, IL-6 and IL-12 levels in cell 
supernatants were evaluated by commercially available 
ELISAs (Biolegend, California) according to the 
manufacturer’s instructions. 
 
MLR. For the MLRs utilizing mouse cells, 5 x 105 
CFSE (2 µM)-labeled allogeneic (Balb-C, H-2K
D
) 
CD4+ cells (responders) were cultured with BMDCs 
(stimulators) from WT or Sirt6KO mice that were 
harvested at day 8 of culture and γ-irradiated (25 Gy). 
Cells were plated in U-bottomed 96-well microplates 
(Nunc) at S:R ratios of 1:5, 1:10, 1:100, and 1:1,000. 
Proliferation of alive (propidium-iodide negative) 
  
www.impactaging.com                     45                                     AGING, January 2016, Vol. 8 No.1
CD3+CD4+CD11c- cells was evaluated by CFSE 
dilution after a 5-day incubation. As a positive control, 
CFSE dilution in response to 5 µg/ml PHA was utilized. 
For the MLRs utilizing human cells, 105 allogeneic 
PBMCs cells (responders) were cultured in 96-well U-
bottomed microplates with 104 stimulator cells 
(moDCs). Proliferation was measured on day 5 with 
ATPliteTM (Perkin Elmer) according to the instructions 
of the manufacturer.  
 
Chemotaxis assays. BMDC Chemotaxis was evaluated 
by a transwell approach. Briefly, 1 x 105 LPS-pretreated 
(overnight)-BMDCs (harvested at day 6) were seeded in 
the upper chamber of 96-well transwell chambers and 
allowed to migrate through a polycarbonate mesh (pore 
size: 5 µm) at 37°C. CCL21 (100 ng/ml; Biolegend, 
CA, USA) or medium alone (as a control for 
spontaneous migration) were placed in the lower 
chamber to assess CCR7-dependent chemotaxis. After 3 
h, cells that had migrated to the lower chamber (150 µl) 
were counted by acquiring a fixed volume with an 
Attune® cytometer. Data were analyzed with the 
Attune® Software v2.1.0. CCL21-dependent migration 
was calculated by subtracting the number of cells that 
had spontaneously migrated. Each experiment was 
performed in duplicate. Values are given as percentage 
of migrated cells and normalized to WT (100%). 
 
qPCR. Total RNA was extracted from cells using the 
RNeasy minikit (Qiagen S.r.l., Milan, Italy) according 
to the manufacturer's instructions. 1 μg of RNA was 
reverse transcribed in a final volume of 50 μl using the 
High Capacity cDNA Reverse Transcription kit 
(Invitrogen). 5 μl of the resulting cDNA was used for 
qPCR with a 7900 HT Fast real-time PCR system 
(Applied Biosystems by Invitrogen) using GoTaq® 
qPCR Master Mix (containing Sybr® green dye) and 
specific primers for mouse Tlr2 Tlr3, Tlr7, Tlr8, 
Unc93b1. All the data obtained were normalized to 
Hprt1 housekeeping gene expression. 
 
Statistical analyses. Data are presented as means ± 
SEM. T-tests were used to assess statistical differences 
between two experimental groups. Graphpad prism 5.0 
software was used for all of the analyses. 
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